Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior

References

• Gimm O, DeMicco C, Perren A, Giammarile F, Walz MK, Brunaud L. Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg. 2012;397:155-77. doi:10.1007/s00423-011-0880-x. PMID:22124609
   PubMed Web of Science ®Google Scholar
• Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep. 2004;6:477-84. doi:10.1007/s11906-004-0044-2. PMID:15527694
   PubMed Web of Science ®Google Scholar
• Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162-8. doi:10.1200/JCO.2008.21.3496. PMID:19636009
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Black JR, Ramaswami R, Tan TM, Adjogatse D, Sharma R. Peptide receptor radionuclide therapy for metastatic paragangliomas. Med Oncol. 2016;33:47. doi:10.1007/s12032-016-0737-9. PMID:27059363
   PubMed Web of Science ®Google Scholar
• Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 2012;118:2804-12. doi:10.1002/cncr.26577. PMID:22006217
   PubMed Web of Science ®Google Scholar
• Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;81:642-51. doi:10.1111/cen.12542. PMID:25041164
   PubMed Web of Science ®Google Scholar
• Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer. 2013;4:103-10. doi:10.1007/s12672-013-0133-2. PMID:23361939
   PubMed Web of Science ®Google Scholar
• Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Fouchardiere C, Libé R, Do Cao C, Niccoli P et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013;98:4006-12. doi:10.1210/jc.2013-1907. PMID:23884775
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. One hundred years after “carcinoid:” epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72. doi:10.1200/JCO.2007.15.4377. PMID:18565894
   PubMed Web of Science ®Google Scholar
• La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. Pharmacotherapy. 2015;35:963-76. doi:10.1002/phar.1643. PMID:26497482
   PubMed Web of Science ®Google Scholar
• Muenst S, Soysal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets. 2015;19:201-11. doi:10.1517/14728222.2014.980235. PMID:25491730
   PubMed Web of Science ®Google Scholar
• Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41:868-76. doi:10.1016/j.ctrv.2015.11.001. PMID:26589760
   PubMed Web of Science ®Google Scholar
• Kluger HM, Zito CR, Turcu G, Baine M, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L et al. PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors. Clin Cancer Res. 2017; 23(15):4270-4279. doi:10.1158/1078-0432.CCR-16-3146. PMID:28223273. [Epub 2017, Feb 21]
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823-33. doi:10.1056/NEJMoa1606774. PMID:27718847
   PubMed Web of Science ®Google Scholar
• Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012;2012:656340. doi:10.1155/2012/656340. PMID:22611421
   PubMedGoogle Scholar
• Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017;23:3158-67. doi:10.1158/1078-0432.CCR-16-1761. PMID:28619999
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27:409-16. doi:10.1093/annonc/mdv615. PMID:26681673
   PubMed Web of Science ®Google Scholar
• Koh YW, Han JH, Park SY, Yoon DH, Suh C, Huh J. GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression. J Pathol Transl Med. 2017;51:152-8. doi:10.4132/jptm.2016.11.03. PMID:28219001
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Ramachandran R, Toussi ST, Vergine M, Ngo N, Sharma R et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer. 2013;108(2):429-37. doi:10.1038/bjc.2012.538. [Epub 2012, Dec 20]
   PubMed Web of Science ®Google Scholar
• Jochmanova I, Yang C, Zhuang Z, Pacak K. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst. 2013;105(17):1270-83. doi:10.1093/jnci/djt201. PMID:23940289. [Epub 2013, Aug 12]
   PubMedGoogle Scholar
• Pinato DJ, Tan TM, Toussi ST, Ramachandran R, Martin N, Meeran K, Ngo N, Dina R, Sharma R. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer. 2014;110:115-22. doi:10.1038/bjc.2013.682. PMID:24231952
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Shiner RJ, White SD, Black JR, Trivedi P, Stebbing J, Sharma R, Mauri FA. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology. 2016;5:e1213934. doi:10.1080/2162402X.2016.1213934. PMID:27757309
   PubMed Web of Science ®Google Scholar
• Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathol. 2014;27:1050-62. doi:10.1038/modpathol.2013.233. PMID:24390213
   PubMed Web of Science ®Google Scholar
• Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005;1:72-80. doi:10.1371/journal.pgen.0010008. PMID:16103922
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Ramachandran R, Toussi ST, Vergine M, Ngo N, Sharma R, Lloyd T, Meeran K, Palazzo F, Martin N et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer. 2013;108:429-37. doi:10.1038/bjc.2012.538. PMID:23257898
   PubMed Web of Science ®Google Scholar
• Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, Chouaib S. Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol. 2015;309:C569-79. doi:10.1152/ajpcell.00207.2015. PMID:26310815
   PubMed Web of Science ®Google Scholar
• Koh YW, Han JH, Park SY, Yoon DH, Suh C, Huh J. GLUT1 as a prognostic factor for classical hodgkin's lymphoma: correlation with PD-L1 and PD-L2 expression. J Pathol Transl Med. 2017;51:152-158. doi:10.4132/jptm.2016.11.03. PMID:28219001
   PubMed Web of Science ®Google Scholar
• Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31:181-93. doi:10.1016/j.ccell.2017.01.001. PMID:28162975
   PubMed Web of Science ®Google Scholar
• Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab. 2006;91:4593-8. doi:10.1210/jc.2006-0920. PMID:16954163
   PubMed Web of Science ®Google Scholar